Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by GW Henssler & Associates Ltd.

Key Points

• GW Henssler & Associates Ltd. increased its stake in Regeneron Pharmaceuticals by 14.3%, acquiring a total of 20,360 shares valued at approximately $12.9 million.
• The company reported earnings of $12.89 EPS for the latest quarter, significantly surpassing analysts' estimates of $8.43 and showing a 3.6% year-over-year revenue growth.
• Regeneron Pharmaceuticals announced a quarterly dividend of $0.88, resulting in an annualized yield of 0.6%, reflecting a low payout ratio of 8.87%.

GW Henssler & Associates Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,360 shares of the biopharmaceutical company's stock after acquiring an additional 2,543 shares during the period. GW Henssler & Associates Ltd.'s holdings in Regeneron Pharmaceuticals were worth $12,913,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of REGN. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Activest Wealth Management grew its position in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $27,000. Finally, Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $27,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday. Guggenheim increased their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday, August 11th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, Jefferies Financial Group increased their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $3.42 during mid-day trading on Thursday, reaching $567.22. The stock had a trading volume of 996,756 shares, compared to its average volume of 1,102,946. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a market cap of $60.12 billion, a P/E ratio of 14.29, a price-to-earnings-growth ratio of 1.93 and a beta of 0.35. The business has a 50-day simple moving average of $560.61 and a 200 day simple moving average of $586.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,175.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 earnings per share. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.